Hi The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women.Tune into Dr Rachael Sumner, who discusses the...

Hi We are progressing this worthwhile clinical research in multiple Phase 2B trials and setting the company up for it's future. Read MoreNEWS RELEASEMINDBIO EXPLORES DUAL LISTING ON A SENIOR EXCHANGE WITH MULTIPLE PHASE 2B CLINICAL TRIALS UNDERWAY SU...

Hi Women remain under-represented in clinical trials, compared to men.A reason often cited, even in our own work, apart from the risk of pregnancy whilst taking an experimental drug, is the varying effects of the menstrual cycle on assessing how the...

Hi It was a surprising discovery in a randomized controlled trial testing microdoses of LSD (MB22001) in 80 healthy people. The data shows a statistically significant improvement in sleep, including total time of sleep and quality of sleep with some...

Hi It's a small step that's taken years in planning and persistence in gaining regulatory approvals for take home use and we are pleased to announce the first dose has been administered.It's a Phase 2B microdosing trial in patients with Major Depress...

Hi It's great news! MindBio has received final regulatory, ethics and ministerial approval to start take-home dosing MB22001 in a Phase 2B trial in patients with Major Depressive Disorder. The mounting evidence for microdosing MB22001 as a scalable,...

Hi We've got great news to report as we progress MB22001 through clinical trials. MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed specifically for take-home self administered microdosing.We're targeting Major Dep...

Hi I am delighted to share with you that MindBio Therapeutics Corp (CNSX: MBIO) has completed its landmark Phase 2a take home microdosing clinical trial in patients with Major Depressive Disorder.MindBio has achieved a significant milestone becoming...

Hi It's a very small dose of a proprietary form of LSD (lysergic acid diethylamide) for take-home microdosing (MB22001) that we have so much hope for in our Phase 2 clinical trials.On 14th February 2024 we will complete the final dose in our Phase 2a...

Hi MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio’s proprietary titratable form of LSD for take-home Microdosing). The final participant in this landmark clinical trial is nea...